Cancer and Leukemia Group B Statistical Center

癌症和白血病B组统计中心

• 批准号: 8467680
• 负责人: DANIEL J. SARGENT
• 金额: $ 431万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-12-01 至 2014-08-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8467680
• 关键词: Address; Adopted; Bioinformatics; Cancer and Leukemia Group B; Clinical Data; Clinical Trials; Collaborations; Conduct Clinical Trials; Data; Data Quality; Databases; Faculty; Grant; Information Systems; Laboratories; Manuscripts; Molecular; Monitor; Organization administrative structures; Process; Publications; Quality Control; Reporting; Research; Research Infrastructure; Research Personnel; Resources; Science; Software Tools; Source; Therapeutic; Tissue Banking; Tissue Banks; Work; base; data management; design; image archival system; improved; protocol development; statistical center

The Cancer and Leukemia Group B (CALGB) Statistical Center has primary responsibility for all statistical, data management, computing, information systems, and related activities for the CALGB. Faculty and staff statisticians and data coordinators collaborate closely with study chairs, committee chairs, and other investigators on the design, conduct, analysis, and reporting of all clinical trials and other studies conducted by the CALGB. The Statistical Center has responsibility for central data quality control and database administration. All clinical data are sent to the Statistical Center for editing, verification, and entry into the official CALGB database. Scientific laboratory data are transmitted electronically and become part of the official record. Statisticians and datacoordinators from the Statistical Center are assigned to each CALGB study. They work closely with study chairs to monitor the studies and to prepare all necessary reports, analyses, and manuscripts.

癌症和白血病 B 组 (CALGB) 统计中心对所有 CALGB 的统计、数据管理、计算、信息系统和相关活动。 教职员工统计学家和数据协调员与研究主席、委员会密切合作 主席和其他研究者负责所有临床试验的设计、实施、分析和报告 CALGB 进行的其他研究。统计中心负责中央数据 质量控制和数据库管理。所有临床数据均送至统计中心进行统计 编辑、验证并录入官方CALGB数据库。科学实验室数据是 以电子方式传输并成为正式记录的一部分。统计学家和数据协调员 来自统计中心的人员被分配到每项 CALGB 研究中。他们与学习椅密切合作 监督研究并准备所有必要的报告、分析和手稿。

项目成果

Between-arm comparisons in randomized Phase II trials.

随机 II 期试验的臂间比较。

• 发表时间: 2009
• 作者: Jung, Sin;George, Stephen L
• 通讯作者: George, Stephen L

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

加利昔单抗（抗 CD80 单克隆抗体）加利妥昔单抗 (CALGB 50402) 的 II 期试验：滤泡性淋巴瘤国际预后指数 (FLIPI) 评分可预测前期免疫治疗反应性。

• 发表时间: 2012-09
• 作者: Czuczman, M S;Leonard, J P;Jung, S;Johnson, J L;Hsi, E D;Byrd, J C;Cheson, B D
• 通讯作者: Cheson, B D

A comparison of two methods for calculating expected mortality.

两种计算预期死亡率方法的比较。

• 发表时间: 1985-01
• 影响因子: 2

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

伊立替康氟尿嘧啶加亚叶酸作为 III 期结肠癌的辅助治疗并不优于单独氟尿嘧啶加亚叶酸：CALGB 89803 的结果。

• DOI: 10.1200/jco.2007.11.2144
• 发表时间: 2007-08-10
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: L. Saltz;D. Niedzwiecki;D. Hollis;R. Goldberg;A. Hantel;James P. Thomas;A. Fields;R. Mayer
• 通讯作者: R. Mayer

Detecting treatment-by-centre interaction in multi-centre clinical trials.

检测多中心临床试验中各中心治疗的相互作用。

• 发表时间: 2001-01-30
• 影响因子: 2
• 作者: Potthoff, R F;Peterson, B L;George, S L
• 通讯作者: George, S L